FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8122人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839678, encodeId=14df18396e898, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=安进/优时比的抗骨硬化蛋白单抗romosozumab，获FDA批准治疗绝经后妇女的骨质疏松症, objectType=article, longId=164049, objectId=df2216404974, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2216404974, replyNumber=0, likeNumber=60, createdTime=2019-12-03, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2216404974, moduleTitle=安进/优时比的抗骨硬化蛋白单抗romosozumab，获FDA批准治疗绝经后妇女的骨质疏松症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2216404974)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839591, encodeId=dad618395911e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准诺华的Gilenya用于儿童和青少年复发型多发性硬化症, objectType=article, longId=138157, objectId=49b413815e84, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49b413815e84, replyNumber=0, likeNumber=56, createdTime=2018-12-24, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49b413815e84, moduleTitle=FDA批准诺华的Gilenya用于儿童和青少年复发型多发性硬化症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49b413815e84)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839626, encodeId=b20e1839626de, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准辉瑞EGFR抑制剂达克替尼用于EGFR突变的局部晚期或转移性NSCLC患者的一线治疗, objectType=article, longId=149971, objectId=bdf71499e193, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdf71499e193, replyNumber=0, likeNumber=71, createdTime=2019-04-18, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdf71499e193, moduleTitle=FDA批准辉瑞EGFR抑制剂达克替尼用于EGFR突变的局部晚期或转移性NSCLC患者的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdf71499e193)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839584, encodeId=d407183958448, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Lilly/Incyte的低剂量JAK抑制剂治疗类风湿性关节炎, objectType=article, longId=136407, objectId=f78d13640ef0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f78d13640ef0, replyNumber=0, likeNumber=60, createdTime=2019-03-21, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f78d13640ef0, moduleTitle=FDA批准Lilly/Incyte的低剂量JAK抑制剂治疗类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f78d13640ef0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839619, encodeId=1b65183961977, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=拜尔A型血友病药物Jivi获得FDA批准, objectType=article, longId=147909, objectId=ab0414e909e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab0414e909e9, replyNumber=0, likeNumber=83, createdTime=2019-03-27, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab0414e909e9, moduleTitle=拜尔A型血友病药物Jivi获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab0414e909e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839643, encodeId=fd7e183964315, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Acorda的Inbrija治疗帕金森病, objectType=article, longId=156683, objectId=edbd15668347, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edbd15668347, replyNumber=0, likeNumber=88, createdTime=2019-04-08, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edbd15668347, moduleTitle=FDA批准Acorda的Inbrija治疗帕金森病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edbd15668347)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839639, encodeId=cae11839639ff, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=经加速审查 FDA批准两款癌症治疗方案, objectType=article, longId=154707, objectId=33f1154e0709, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33f1154e0709, replyNumber=0, likeNumber=44, createdTime=2018-12-15, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33f1154e0709, moduleTitle=经加速审查 FDA批准两款癌症治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33f1154e0709)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839650, encodeId=9b981839650b5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Imbruvica和Gazyvo联用获FDA批准用于治疗慢性淋巴细胞白血病, objectType=article, longId=159146, objectId=e3eb15914659, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3eb15914659, replyNumber=0, likeNumber=70, createdTime=2019-06-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3eb15914659, moduleTitle=Imbruvica和Gazyvo联用获FDA批准用于治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3eb15914659)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839625, encodeId=ff371839625d2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Lilly的CGRP单抗Emgality用于预防偏头痛, objectType=article, longId=149964, objectId=f791149964f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f791149964f3, replyNumber=0, likeNumber=64, createdTime=2019-08-11, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f791149964f3, moduleTitle=FDA批准Lilly的CGRP单抗Emgality用于预防偏头痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f791149964f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839634, encodeId=7c731839634b9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘, objectType=article, longId=151494, objectId=a936151494c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a936151494c3, replyNumber=0, likeNumber=57, createdTime=2019-05-02, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a936151494c3, moduleTitle=赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a936151494c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839595, encodeId=1c6e1839595af, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准辉瑞的Xeljanz治疗溃疡性结肠炎, objectType=article, longId=139663, objectId=a442139663e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a442139663e4, replyNumber=0, likeNumber=77, createdTime=2018-08-14, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a442139663e4, moduleTitle=FDA批准辉瑞的Xeljanz治疗溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a442139663e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839614, encodeId=e009183961421, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准Omadacycline抗生素上市, objectType=article, longId=146516, objectId=1f8a146516ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f8a146516ba, replyNumber=0, likeNumber=76, createdTime=2019-05-14, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f8a146516ba, moduleTitle=美国FDA批准Omadacycline抗生素上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f8a146516ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839598, encodeId=64ba1839598df, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=J Natl Cancer Inst：FDA批准的抗癌新药一半以上然并卵, objectType=article, longId=140227, objectId=37dc14022e77, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37dc14022e77, replyNumber=0, likeNumber=54, createdTime=2019-05-01, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37dc14022e77, moduleTitle=J Natl Cancer Inst：FDA批准的抗癌新药一半以上然并卵, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37dc14022e77)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839636, encodeId=85231839636d1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Seattle Genetics的Adcetris治疗外周T细胞淋巴瘤, objectType=article, longId=153842, objectId=37411538422c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37411538422c, replyNumber=0, likeNumber=76, createdTime=2019-01-16, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37411538422c, moduleTitle=FDA批准Seattle Genetics的Adcetris治疗外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37411538422c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839615, encodeId=37281839615bb, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=20年等待！FDA批准基于诺奖技术的新疗法, objectType=article, longId=146638, objectId=f61b146638d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f61b146638d7, replyNumber=0, likeNumber=69, createdTime=2019-01-15, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f61b146638d7, moduleTitle=20年等待！FDA批准基于诺奖技术的新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f61b146638d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839596, encodeId=cd85183959651, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准人工虹膜有望解决患者困扰, objectType=article, longId=139676, objectId=0a971396e687, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a971396e687, replyNumber=0, likeNumber=53, createdTime=2018-08-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a971396e687, moduleTitle=美国FDA批准人工虹膜有望解决患者困扰, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a971396e687)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839593, encodeId=15ea183959310, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Doptelet用于血小板减少症的治疗, objectType=article, longId=138880, objectId=fde5138880de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fde5138880de, replyNumber=0, likeNumber=88, createdTime=2018-10-19, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fde5138880de, moduleTitle=FDA批准Doptelet用于血小板减少症的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fde5138880de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839624, encodeId=8165183962405, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准高纯度鱼油新药有助治疗心脏病和中风, objectType=article, longId=149858, objectId=f12314985890, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f12314985890, replyNumber=0, likeNumber=0, createdTime=2019-01-06, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f12314985890, moduleTitle=FDA批准高纯度鱼油新药有助治疗心脏病和中风, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f12314985890)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839635, encodeId=4fcb1839635c2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Mylan与Theravance制药的Yupelri被FDA批准用于COPD, objectType=article, longId=153277, objectId=e21c1532e78b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e21c1532e78b, replyNumber=0, likeNumber=96, createdTime=2019-02-14, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e21c1532e78b, moduleTitle=Mylan与Theravance制药的Yupelri被FDA批准用于COPD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e21c1532e78b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839601, encodeId=6d4a18396015a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准GW制药的Epidiolex用于治疗癫痫, objectType=article, longId=141717, objectId=04d4141e179a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04d4141e179a, replyNumber=0, likeNumber=83, createdTime=2019-03-29, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04d4141e179a, moduleTitle=FDA批准GW制药的Epidiolex用于治疗癫痫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04d4141e179a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

安进/优时比的抗骨硬化蛋白单抗romosozumab，获FDA批准治疗绝经后妇女的骨质疏松症

2019-12-03

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准诺华的Gilenya用于儿童和青少年复发型多发性硬化症

2018-12-24

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准辉瑞EGFR抑制剂达克替尼用于EGFR突变的局部晚期或转移性NSCLC患者的一线治疗

2019-04-18

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Lilly/Incyte的低剂量JAK抑制剂治疗类风湿性关节炎

2019-03-21

docwu2019 (审核中...)

前往app查看评论内容

#FDA批准#

拜尔A型血友病药物Jivi获得FDA批准

2019-03-27

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Acorda的Inbrija治疗帕金森病

2019-04-08

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

经加速审查 FDA批准两款癌症治疗方案

2018-12-15

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

Imbruvica和Gazyvo联用获FDA批准用于治疗慢性淋巴细胞白血病

2019-06-28

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Lilly的CGRP单抗Emgality用于预防偏头痛

2019-08-11

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘

2019-05-02

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准辉瑞的Xeljanz治疗溃疡性结肠炎

2018-08-14

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准Omadacycline抗生素上市

2019-05-14

bugit (审核中...)

前往app查看评论内容

#FDA批准#

J Natl Cancer Inst：FDA批准的抗癌新药一半以上然并卵

2019-05-01

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Seattle Genetics的Adcetris治疗外周T细胞淋巴瘤

2019-01-16

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

20年等待！FDA批准基于诺奖技术的新疗法

2019-01-15

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准人工虹膜有望解决患者困扰

2018-08-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Doptelet用于血小板减少症的治疗

2018-10-19

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准高纯度鱼油新药有助治疗心脏病和中风

2019-01-06

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

Mylan与Theravance制药的Yupelri被FDA批准用于COPD

2019-02-14

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准GW制药的Epidiolex用于治疗癫痫

2019-03-29

科室
- - 订阅+
  - 更多科室
工具
服务